

Duchenne

Data Platforms

Elizabeth Vroom Chair, World Duchenne Organization EMA Multi-stakeholder Workshop 21 September 2022


Foundation 29

Position of the DMD Patient community

- Optimal (re)use of data for drug development and care <u>https://www.worldduchenne.org/fair-data-for-duchenne/</u>
- Collection of data relevant to patients (PROs and PROMs) 'Need for Natural History of PROMs'
- Placebo data should be made available
- Clinical trial data should be returned to participants
- Patients should decide about the (re)use of their own data
- Patients and citizens are willing and interested to share data
- Data centralization and the old data transfer process are roadblocks for scientific research. Let's change that


Data platform(s)

- To be used for questions relevant to the patient community whether it is **development of new drugs**, new technologies or about daily life
- Give patients the power and control over the use of their own data
- Allow to have all their data with them at all times (emergencies)
- To give patients the option to 'get their data together'. See it as 'storing in a personal locker'
- To facilitate the adoption of emerging technologies regarding data collection and enable their optimal application in health research, care and drug development



EHDS

- Conforming to GDPR obligations
- DMD data was made (FAIR)
 - International
 Standards
 recommended at
 European level
 were used
 (European Joint
 Programme on
 Rare Diseases
 (EJP-RD))



1st September, 2022 - Announcement by Joint Press Release



Another initiative by Foundation 29

RAITO Decentralized patient registries



- Uses PODs technology that empowers rare disease patients with their data to be able to activate applications and connections with organizations such as pharmaceutical companies and regulators
- Patient Organizations aggregate anonymous data from Raito's network of patients
- Patient Organizations can send questionnaires to collect data
- Patient Organizations can share these data for drug development or other projects

Thank you for your attention!

(Also on behalf of Julián Isla, Foundation 29)